PMID- 22275377 OWN - NLM STAT- MEDLINE DCOM- 20120501 LR - 20211021 IS - 1083-351X (Electronic) IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 287 IP - 11 DP - 2012 Mar 9 TI - Impaired transforming growth factor-beta (TGF-beta) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1). PG - 8584-97 LID - 10.1074/jbc.M112.341958 [doi] AB - Multiple endocrine neoplasia type 1 (MEN1) is characterized by tumors of the parathyroid, enteropancreas, and anterior pituitary. The MEN1 gene encodes the tumor suppressor menin of 610 amino acids that has multiple protein partners and activities. The particular pathways that, when lost, lead to tumorigenesis are not known. We demonstrated that members of a three-generation MEN1 kindred are heterozygous for a donor splice site mutation at the beginning of intron 3 (IVS3 + 1G-->A). Lymphoblastoid cells of a mutant gene carrier had, in addition to the wild-type menin transcript, an aberrant transcript resulting from use of a cryptic splice site within exon III that splices to the start of exon IV. The predicted menin Delta(184-218) mutant has an in-frame deletion of 35 amino acids but is otherwise of wild-type sequence. The transfected menin Delta(184-218) mutant was well expressed and fully able to mediate the normal inhibition of the activity of the transcriptional regulators JunD and NF-kappaB. However, it was defective in mediating TGF-beta-stimulated Smad3 action in promoter-reporter assays in insulinoma cells. Importantly, lymphoblastoid cells from an individual heterozygous for the mutation had reduced TGF-beta-induced (Smad3) transcriptional activity but normal JunD and NF-kappaB function. In addition, the mutant gene carrier lymphoblastoid cells proliferated faster and were less responsive to the cytostatic effects of TGF-beta than cells from an unaffected family member. In conclusion, the menin mutant exhibits selective loss of the TGF-beta signaling pathway and loss of cell proliferation control contributing to the development of MEN1. FAU - Canaff, Lucie AU - Canaff L AD - Department of Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec H3A 1A1, Canada. FAU - Vanbellinghen, Jean-Francois AU - Vanbellinghen JF FAU - Kaji, Hiroshi AU - Kaji H FAU - Goltzman, David AU - Goltzman D FAU - Hendy, Geoffrey N AU - Hendy GN LA - eng GR - MOP-86703/Canadian Institutes of Health Research/Canada GR - MOP-9315/Canadian Institutes of Health Research/Canada PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120124 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (JunD protein, human) RN - 0 (MEN1 protein, human) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Proto-Oncogene Proteins c-jun) RN - 0 (RNA Splice Sites) RN - 0 (SMAD3 protein, human) RN - 0 (Smad3 Protein) RN - 0 (Transforming Growth Factor beta) SB - IM MH - Adolescent MH - Adult MH - Aged, 80 and over MH - Amino Acid Sequence/*genetics MH - Animals MH - Cell Line, Tumor MH - Cell Proliferation MH - Female MH - Humans MH - Introns MH - Male MH - Middle Aged MH - Multiple Endocrine Neoplasia Type 1/genetics/*metabolism/pathology MH - Proto-Oncogene Proteins/genetics/*metabolism MH - Proto-Oncogene Proteins c-jun/genetics/metabolism MH - RNA Splice Sites/*genetics MH - Rats MH - *Sequence Deletion MH - *Signal Transduction MH - Smad3 Protein/genetics/metabolism MH - Transforming Growth Factor beta/genetics/*metabolism PMC - PMC3318699 EDAT- 2012/01/26 06:00 MHDA- 2012/05/02 06:00 PMCR- 2013/03/09 CRDT- 2012/01/26 06:00 PHST- 2012/01/26 06:00 [entrez] PHST- 2012/01/26 06:00 [pubmed] PHST- 2012/05/02 06:00 [medline] PHST- 2013/03/09 00:00 [pmc-release] AID - S0021-9258(20)61003-1 [pii] AID - M112.341958 [pii] AID - 10.1074/jbc.M112.341958 [doi] PST - ppublish SO - J Biol Chem. 2012 Mar 9;287(11):8584-97. doi: 10.1074/jbc.M112.341958. Epub 2012 Jan 24.